BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 7914428)

  • 21. Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients.
    de Wit R; Kruit WH; Stoter G; de Boer M; Kerger J; Verweij J
    Br J Cancer; 1998 Nov; 78(10):1342-5. PubMed ID: 9823976
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan.
    Okada S; Sakata Y; Matsuno S; Kurihara M; Sasaki Y; Ohashi Y; Taguchi T
    Br J Cancer; 1999 May; 80(3-4):438-43. PubMed ID: 10408850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II studies of docetaxel in the treatment of various solid tumours. EORTC Early Clinical Trials Group and the EORTC Soft Tissue and Bone Sarcoma Group.
    Verweij J; Catimel G; Sulkes A; Sternberg C; Wolff I; Aamdal S; van Hoesel Q
    Eur J Cancer; 1995; 31A Suppl 4():S21-4. PubMed ID: 7577101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study.
    Freyer G; Hennebert P; Awada A; Gil T; Kerger J; Selleslags J; Brassinne C; Piccart M; de Valeriola D
    Clin Cancer Res; 2002 Jan; 8(1):95-102. PubMed ID: 11801544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group.
    van Hoesel QG; Verweij J; Catimel G; Clavel M; Kerbrat P; van Oosterom AT; Kerger J; Tursz T; van Glabbeke M; van Pottelsberghe C
    Ann Oncol; 1994 Jul; 5(6):539-42. PubMed ID: 7918126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Efficacy of docetaxel in non-small cell lung cancer patients previously treated with platinum-containing chemotherapy. French Group of Pneumo-Cancerology].
    Robinet G; Thomas P; Pérol M; Vergnenègre A; Lena H; Taytard A; Paillotin D; Bessa EH; Schuller-Lebeau MP
    Rev Mal Respir; 2000 Feb; 17(1):83-9. PubMed ID: 10756559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [An early phase II clinical study of RP56976 (docetaxel) in patients with cancer of the gastrointestinal tract].
    Taguchi T
    Gan To Kagaku Ryoho; 1994 Oct; 21(14):2431-7. PubMed ID: 7944488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Phase II study of docetaxel in inoperable advanced non small cell lung cancer].
    Robinet G; Thomas P; Pérol M; Vergnenegre A; Lena H; Taytard A; Paillotin D; Bessa EH; Schuller-Lebeau MP
    Bull Cancer; 2000 Mar; 87(3):253-8. PubMed ID: 10779813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer.
    Cascinu S; Graziano F; Barni S; Labianca R; Comella G; Casaretti R; Frontini L; Catalano V; Baldelli AM; Catalano G
    Br J Cancer; 2001 Feb; 84(4):470-4. PubMed ID: 11207039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer.
    Francis P; Schneider J; Hann L; Balmaceda C; Barakat R; Phillips M; Hakes T
    J Clin Oncol; 1994 Nov; 12(11):2301-8. PubMed ID: 7964944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Docetaxel in advanced renal carcinoma. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group.
    Mertens WC; Eisenhauer EA; Jolivet J; Ernst S; Moore M; Muldal A
    Ann Oncol; 1994 Feb; 5(2):185-7. PubMed ID: 7910480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study.
    Kunitoh H; Watanabe K; Onoshi T; Furuse K; Niitani H; Taguchi T
    J Clin Oncol; 1996 May; 14(5):1649-55. PubMed ID: 8622084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.
    Piccart MJ; Klijn J; Paridaens R; Nooij M; Mauriac L; Coleman R; Bontenbal M; Awada A; Selleslags J; Van Vreckem A; Van Glabbeke M
    J Clin Oncol; 1997 Sep; 15(9):3149-55. PubMed ID: 9294478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.
    Valero V; Holmes FA; Walters RS; Theriault RL; Esparza L; Fraschini G; Fonseca GA; Bellet RE; Buzdar AU; Hortobagyi GN
    J Clin Oncol; 1995 Dec; 13(12):2886-94. PubMed ID: 8523051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial.
    Bang YJ; Kang WK; Kang YK; Kim HC; Jacques C; Zuber E; Daglish B; Boudraa Y; Kim WS; Heo DS; Kim NK
    Jpn J Clin Oncol; 2002 Jul; 32(7):248-54. PubMed ID: 12324575
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: a Southwest Oncology Group phase II trial.
    Hesketh PJ; Crowley JJ; Burris HA; Williamson SK; Balcerzak SP; Peereboom D; Goodwin JW; Gross HM; Moore DF; Livingston RB; Gandara DR
    Cancer J Sci Am; 1999; 5(4):237-41. PubMed ID: 10439170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
    Valero V
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):34-6. PubMed ID: 9364540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial.
    Shitara K; Takashima A; Fujitani K; Koeda K; Hara H; Nakayama N; Hironaka S; Nishikawa K; Makari Y; Amagai K; Ueda S; Yoshida K; Shimodaira H; Nishina T; Tsuda M; Kurokawa Y; Tamura T; Sasaki Y; Morita S; Koizumi W
    Lancet Gastroenterol Hepatol; 2017 Apr; 2(4):277-287. PubMed ID: 28404157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma.
    McCaffrey JA; Hilton S; Mazumdar M; Sadan S; Kelly WK; Scher HI; Bajorin DF
    J Clin Oncol; 1997 May; 15(5):1853-7. PubMed ID: 9164195
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Docetaxel (Taxotere): an overview of first-line monotherapy.
    Trudeau ME
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):17-21. PubMed ID: 8604448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.